The newest generation of antiobesity medications (AOMs)—GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), dual action GLP-1/GIP combinations, triple action injectables, and emerging injectable and oral medications—have changed the landscape for weight management, bringing weight loss success to many for whom weight maintenance had previously not been possible.
Trending
- Study May Explain Why IBD Patients React to Foods They Once Tolerated
- New Position Statement Linking Human Health and Planetary Health
- Navigating Personalized Nutrition Tech in Dietetic Practice
- Savoring San Antonio
- The Emerging Role of Metabolic Psychiatry
- Culinary Sports Nutrition
- Traumatic Brain Injury and Nutrition Support
- CPE Monthly: Targeted Nutrition Interventions for Short Bowel